177Lu-PSMA I&T_IRSTIRCCS

DRUG2 trials

Sponsors

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Conditions

Oligometastatic prostate carcinomaPSMA PET/CT positive advanced/metastatic tumours

Phase 2

A phase II randomized trial of Lu-PSMA and Stereotactic Radiotherapy versus Radiotherapy alone for oligometastatic prostate cancer (LUST)

RecruitingCTIS2024-519347-15-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.Oligometastatic prostate carcinoma

Start: 2023-06-27Target: 70Updated: 2025-07-14

Radiometabolic Therapy (RMT) with 177Lu PSMA in PSMA PET/CT positive advanced/metastatic tumours: a basket trial (LUBASKET)

Active, not recruitingCTIS2024-519346-75-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.PSMA PET/CT positive advanced/metastatic tumours

Start: 2023-05-25Target: 83Updated: 2025-01-15